Back to Peptides
PerformanceHigh Risk

ACE-031

Also known as: ACVR2B-Fc, Ramatercept

Half-life:
~14 days

Administration Routes

subcutaneous injectionintravenous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

A soluble decoy receptor that blocks the ActRIIB pathway, inhibiting myostatin and related TGF-β family proteins. Produces dramatic muscle and bone gains but carries cardiovascular risks at high doses.

Primary Research Areas

  • myostatin/activin inhibition
  • muscle mass increase
  • bone density improvement

Risk Profile

High Risk

Higher risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyInvestigational

Activin receptor IIB-Fc fusion (ACVR2B decoy) by Acceleron Pharma. Phase 2 for Duchenne MD halted 2013 due to AEs (epistaxis, telangiectasia). Development discontinued. Previously held IND.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find ACE-031